Navitas Semiconductor Corporation Common Stock vs Repligen Corporation Common Stock — how do they compare? Navitas Semiconductor Corporation Common Stock trades at $9.08 (market cap $2.63B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 4.2× Navitas Semiconductor Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Navitas Semiconductor Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Navitas Semiconductor Corporation Common Stock for 3 Days and Repligen Corporation Common Stock for 0 Days on average.
| NVTS | RGEN | |
|---|---|---|
Market Cap | $2.63B | $11.14B |
Volume | 20,633,069 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $31.79 | $194.57 |
52-Week Low | $7.14 | $102.87 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $2.07B | $11.02B |
Signals from Pluang's Aura AI — not financial advice
Navitas Semiconductor (NVTS) trades at $10.45, up 4.6% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal overall, with moving averages indicating selling pressure, but oscillators suggest some bullish momentum. Fundamentally, the company is in a growth investment phase, reporting negative net income margins and significant cash burn from operations, offset by strong financing inflows. Recent news highlights strategic collaborations with NVIDIA and Microchip for AI data center power solutions and a U.S. Army contract for silicon carbide chip development, positioning NVTS in high-growth power semiconductor markets.
The outlook for NVTS hinges on execution in the AI and defense power semiconductor segments, with a consensus price target of $16.65 implying substantial upside. However, high valuation multiples, persistent losses, and competitive intensity pose significant risks. Investors should weigh the company's promising market positioning against its current lack of profitability and the capital-intensive nature of its expansion.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Navitas Semiconductor designs and markets gallium nitride and silicon carbide power semiconductors. Its products are used in power conversion and charging for data centers, energy infrastructure, and industrial applications.
Read more on NVTS →Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →